Screening for inhibitors of allergen-associated airway smooth muscle contraction
筛选过敏原相关气道平滑肌收缩抑制剂
基本信息
- 批准号:10176398
- 负责人:
- 金额:$ 21.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAffinityAlamarBlueAllergensAllergic inflammationAnimalsAntifungal AgentsAspergillus fumigatusAsthmaBiological AssayBiological SciencesBronchoconstrictionBronchodilator AgentsCell SurvivalCytoskeletonDataDinoprostoneDiseaseDoseEvaluationExtracellular MatrixFocal AdhesionsGene ExpressionGenerationsHumanHypersensitivityIgEInflammatoryInhalationLeadLifeLungMeasurementMediatingMediator of activation proteinMoldsMucous MembraneMusMuscle ContractionMycosesN-CadherinPatientsPeptide HydrolasesProductionSafetySchemeSerine ProteaseSerine Proteinase InhibitorsSignal PathwaySliceSmooth Muscle MyocytesStress FibersSubmucosaSymptomsTestingTherapeuticToxic effectValidationaggressive therapyairway hyperresponsivenessalkalinityanti-IgEasthmaticasthmatic airway smooth muscleasthmatic patientattenuationbasecomparativeconstrictioncytokinecytotoxicitydesigndrug candidatedruggable targetexperiencefollow-upfungushigh throughput screeningin vivoinhibitor/antagonistinsightnovelomalizumabprecision medicineprotein expressionpublic health relevancerespiratory smooth musclescreeningsmall molecular inhibitorsmall molecule inhibitortherapeutic target
项目摘要
PROJECT SUMMARY
Despite aggressive treatment with high-dose inhaled corticosteroids plus bronchodilators, approximately 5-10%
of people with asthma (15-30 million) experience severe and life-threatening symptoms of bronchoconstriction.
Nearly one-half of these severe asthma patients are also “sensitized” (i.e. have IgE mediated allergy) to common
molds such as Aspergillus fumigatus (Af). This condition has now been recognized as a distinct entity and
designated fungal asthma (FA). Unfortunately, current therapies for FA—antifungals and/or omalizumab (anti-
IgE)—have not proven to be efficacious in the long-term.
By studying Af-induced bronchoconstriction in mice and people with asthma, our team has discovered a novel,
direct, and druggable target in FA—the Af allergen-derived serine protease, alkaline protease 1 (Alp1). Alp1
promotes the defining symptom of FA—bronchoconstriction—by inducing airway smooth muscle (ASM)
contraction, through mechanisms that appear to be independent of allergic inflammation. In this application, we
will pursue the hypothesis that inhibitors of Alp1-induced human ASM contraction can be discovered by high
throughput screening (HTS). In aim 1, we will use HTS to identify small molecular inhibitors of Alp1 protease. In
aim 2, we will examine the effects of FA pathobiology on the efficacy of Alp1-inhibitor therapy. In aim 3, we will
determine mechanism and examine significance for Alp1-inhibitor therapy. We expect our approach to identify
novel anti-FA drug candidates, and in doing so, offer substantial insight into both ASM-intrinsic and allergen
protease dependent mechanisms of bronchoconstriction.
项目摘要
尽管使用大剂量吸入性皮质类固醇加支气管扩张剂进行了积极治疗,
的哮喘患者(1500 - 3000万)经历严重和危及生命的支气管收缩症状。
这些严重哮喘患者中有近一半还对常见的过敏原“敏感”(即具有IgE介导的过敏)。
霉菌如烟曲霉(Af)。这种情况现在已被确认为一个独特的实体,
真菌性哮喘(FA)不幸的是,FA-抗真菌剂和/或奥马珠单抗(抗真菌药)的当前疗法是不理想的。
IgE)-尚未证明长期有效。
通过研究小鼠和哮喘患者中AF诱导的支气管收缩,我们的团队发现了一种新的,
FA中的直接、可药用靶标-Af变应原衍生的丝氨酸蛋白酶,碱性蛋白酶1(Alp 1)。Alp1
通过诱导气道平滑肌(ASM)促进FA的定义症状-支气管收缩
收缩,通过似乎独立于过敏性炎症的机制。在本申请中,我们
将继续研究Alp 1诱导的人ASM收缩抑制剂可以通过高通量的方法发现的假设。
通量筛选(HTS)。在目标1中,我们将使用HTS来鉴定Alp 1蛋白酶的小分子抑制剂。在
目的2,我们将检查FA病理生物学对Alp 1抑制剂治疗效果的影响。在目标3中,我们
确定Alp 1抑制剂治疗的机制和意义。我们希望我们的方法能够识别
新的抗FA候选药物,并在这样做,提供了实质性的洞察ASM的内在和过敏原
支气管收缩的蛋白酶依赖机制。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Multiscale stiffness of human emphysematous precision cut lung slices.
- DOI:10.1126/sciadv.adf2535
- 发表时间:2023-05-19
- 期刊:
- 影响因子:13.6
- 作者:Kim, Jae Hun;Schaible, Niccole;Hall, Joseph K.;Bartolak-Suki, Erzsebet;Deng, Yuqing;Herrmann, Jacob;Sonnenberg, Adam;Behrsing, Holger P.;Lutchen, Kenneth R.;Krishnan, Ramaswamy;Suki, Bela
- 通讯作者:Suki, Bela
CD38 plays an age-related role in cholinergic deregulation of airway smooth muscle contractility.
- DOI:10.1016/j.jaci.2021.10.033
- 发表时间:2022-05
- 期刊:
- 影响因子:14.2
- 作者:Bai, Yan;Guedes, Alonso G. P.;Krishnan, Ramaswamy;Ai, Xingbin
- 通讯作者:Ai, Xingbin
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAMASWAMY KRISHNAN其他文献
RAMASWAMY KRISHNAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAMASWAMY KRISHNAN', 18)}}的其他基金
Screening for inhibitors of allergen-associated airway smooth muscle contraction
筛选过敏原相关气道平滑肌收缩抑制剂
- 批准号:
10057021 - 财政年份:2020
- 资助金额:
$ 21.88万 - 项目类别:
Cooperative targeting of pharmacomechanical coupling and the actin cytoskeleton to regulate ASM contraction
药物机械耦合和肌动蛋白细胞骨架的协同靶向调节 ASM 收缩
- 批准号:
9983151 - 财政年份:2019
- 资助金额:
$ 21.88万 - 项目类别:
Cooperative targeting of pharmacomechanical coupling and the actin cytoskeleton to regulate ASM contraction
药物机械耦合和肌动蛋白细胞骨架的协同靶向调节 ASM 收缩
- 批准号:
10188621 - 财政年份:2019
- 资助金额:
$ 21.88万 - 项目类别:
Cooperative targeting of pharmacomechanical coupling and the actin cytoskeleton to regulate ASM contraction
药物机械耦合和肌动蛋白细胞骨架的协同靶向调节 ASM 收缩
- 批准号:
10434061 - 财政年份:2019
- 资助金额:
$ 21.88万 - 项目类别:
Monitoring contractile forces during airway constriction
监测气道收缩期间的收缩力
- 批准号:
9318550 - 财政年份:2016
- 资助金额:
$ 21.88万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 21.88万 - 项目类别:
Continuing Grant